Literature DB >> 31261134

Cavernous angiomas: deconstructing a neurosurgical disease.

Issam A Awad, Sean P Polster.   

Abstract

Cavernous angioma (CA) is also known as cavernoma, cavernous hemangioma, and cerebral cavernous malformation (CCM) (National Library of Medicine Medical Subject heading unique ID D006392). In its sporadic form, CA occurs as a solitary hemorrhagic vascular lesion or as clustered lesions associated with a developmental venous anomaly. In its autosomal dominant familial form (Online Mendelian Inheritance in Man #116860), CA is caused by a heterozygous germline loss-of-function mutation in one of three genes-CCM1/KRIT1, CCM2/Malcavernin, and CCM3/PDCD10-causing multifocal lesions throughout the brain and spinal cord.In this paper, the authors review the cardinal features of CA's disease pathology and clinical radiological features. They summarize key aspects of CA's natural history and broad elements of evidence-based management guidelines, including surgery. The authors also discuss evidence of similar genetic defects in sporadic and familial lesions, consequences of CCM gene loss in different tissues at various stages of development, and implications regarding the pathobiology of CAs.The concept of CA with symptomatic hemorrhage (CASH) is presented as well as its relevance to clinical care and research in the field. Pathobiological mechanisms related to CA include inflammation and immune-mediated processes, angiogenesis and vascular permeability, microbiome driven factors, and lesional anticoagulant domains. These mechanisms have motivated the development of imaging and plasma biomarkers of relevant disease behavior and promising therapeutic targets.The spectrum of discoveries about CA and their implications endorse CA as a paradigm for deconstructing a neurosurgical disease.

Entities:  

Keywords:  CA = cavernous angioma; CASH = CA with symptomatic hemorrhage; CCM = cerebral cavernous malformation; CD14 = cluster of differentiation 14; DCEQP = dynamic contrast enhanced quantitative perfusion; DVA = developmental venous anomaly; FDR = false discovery rate; MEKK = mitogen-activated protein kinase kinase; QSM = quantitative susceptibility mapping; SRS = stereotactic radiosurgery; SWI/VenBold = susceptibility weighted imaging/BOLD venographic imaging; T2*/GRE = gradient recalled echo acquired; TLR4 = toll-like receptor 4; VEGF = vascular endothelial growth factor; angioma; cavernoma; cavernous; epilepsy; hemangioma; hemorrhagic stroke; sCD14 = soluble form of CD14; sROBO4 = soluble form of Roundabout 4; vascular disorders; vascular malformation

Year:  2019        PMID: 31261134      PMCID: PMC6778695          DOI: 10.3171/2019.3.JNS181724

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  109 in total

1.  Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.

Authors:  Sean P Polster; Agnieszka Stadnik; Amy L Akers; Ying Cao; Gregory A Christoforidis; Maged D Fam; Kelly D Flemming; Romuald Girard; Nicholas Hobson; James I Koenig; Janne Koskimäki; Karen Lane; James K Liao; Cornelia Lee; Seán B Lyne; Nichol McBee; Leslie Morrison; Kristina Piedad; Robert Shenkar; Matthew Sorrentino; Richard E Thompson; Kevin J Whitehead; Hussein A Zeineddine; Daniel F Hanley; Issam A Awad
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

Review 2.  Treatment of multiple sclerosis with anti-CD20 antibodies.

Authors:  Barbara Barun; Amit Bar-Or
Journal:  Clin Immunol       Date:  2011-04-15       Impact factor: 3.969

3.  Brainstem cavernous malformations: 1390 surgical cases from the literature.

Authors:  Bradley A Gross; H Hunt Batjer; Issam A Awad; Bernard R Bendok; Rose Du
Journal:  World Neurosurg       Date:  2012-04-05       Impact factor: 2.104

4.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

5.  Seizure outcome after lesionectomy for cavernous malformations.

Authors:  D S Cohen; G P Zubay; R R Goodman
Journal:  J Neurosurg       Date:  1995-08       Impact factor: 5.115

6.  Results of surgery for cavernomas in critical supratentorial areas.

Authors:  A Pasqualin; P Meneghelli; A Giammarusti; S Turazzi
Journal:  Acta Neurochir Suppl       Date:  2014

7.  Radiation-induced cavernous hemangiomas of the brain: a late effect predominantly in children.

Authors:  Stefan Heckl; Alfred Aschoff; Stefan Kunze
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

8.  Flexible omnidirectional carbon dioxide laser as an effective tool for resection of brainstem, supratentorial, and intramedullary cavernous malformations.

Authors:  Omar Choudhri; Jason Karamchandani; Peter Gooderham; Gary K Steinberg
Journal:  Neurosurgery       Date:  2014-03       Impact factor: 4.654

9.  Surgical management and long-term outcome of pediatric patients with different subtypes of epilepsy associated with cerebral cavernous malformations.

Authors:  Christian von der Brelie; Stefan Kuczaty; Marec von Lehe
Journal:  J Neurosurg Pediatr       Date:  2014-04-04       Impact factor: 2.375

10.  Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.

Authors:  Zinan Zhou; Alan T Tang; Weng-Yew Wong; Sharika Bamezai; Lauren M Goddard; Robert Shenkar; Su Zhou; Jisheng Yang; Alexander C Wright; Matthew Foley; J Simon C Arthur; Kevin J Whitehead; Issam A Awad; Dean Y Li; Xiangjian Zheng; Mark L Kahn
Journal:  Nature       Date:  2016-03-30       Impact factor: 49.962

View more
  22 in total

1.  Radiosurgery for Symptomatic Cavernous Malformation in the Brainstem: Two Difficult Cases with Large and Multiple Lesions.

Authors:  Yoshihisa Kida
Journal:  Cureus       Date:  2019-12-31

2.  Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease.

Authors:  Abhinav Srinath; Ying Li; Romuald Girard; Issam A Awad; Sharbel G Romanos; Bingqing Xie; Chang Chen; Yan Li; Thomas Moore; Dehua Bi; Je Yeong Sone; Rhonda Lightle; Nick Hobson; Dongdong Zhang; Janne Koskimäki; Le Shen; Sara McCurdy; Catherine Chinhchu Lai; Agnieszka Stadnik; Kristina Piedad; Julián Carrión-Penagos; Abdallah Shkoukani; Daniel Snellings; Robert Shenkar; Dinanath Sulakhe; Yuan Ji; Miguel A Lopez-Ramirez; Mark L Kahn; Douglas A Marchuk; Mark H Ginsberg
Journal:  Transl Stroke Res       Date:  2022-06-17       Impact factor: 6.829

3.  Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.

Authors:  Matthieu Peyre; Danielle Miyagishima; Franck Bielle; Françoise Chapon; Michael Sierant; Quitterie Venot; Julie Lerond; Pauline Marijon; Samiya Abi-Jaoude; Tuan Le Van; Karim Labreche; Richard Houlston; Maxime Faisant; Stéphane Clémenceau; Anne-Laure Boch; Aurelien Nouet; Alexandre Carpentier; Julien Boetto; Angeliki Louvi; Michel Kalamarides
Journal:  N Engl J Med       Date:  2021-09-09       Impact factor: 91.245

4.  Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth.

Authors:  Je Yeong Sone; Nicholas Hobson; Abhinav Srinath; Sharbel G Romanos; Ying Li; Julián Carrión-Penagos; Abdallah Shkoukani; Agnieszka Stadnik; Kristina Piedad; Rhonda Lightle; Thomas Moore; Dorothy DeBiasse; Dehua Bi; Robert Shenkar; Timothy Carroll; Yuan Ji; Romuald Girard; Issam A Awad
Journal:  J Magn Reson Imaging       Date:  2021-09-24       Impact factor: 5.119

5.  Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu.

Authors:  Dongdong Zhang; Andrew J Kinloch; Abhinav Srinath; Robert Shenkar; Romuald Girard; Rhonda Lightle; Thomas Moore; Janne Koskimäki; Azam Mohsin; Julián Carrión-Penagos; Sharbel Romanos; Le Shen; Marcus R Clark; Changbin Shi; Issam A Awad
Journal:  J Autoimmun       Date:  2020-04-30       Impact factor: 7.094

6.  CCM2-deficient endothelial cells undergo a ROCK-dependent reprogramming into senescence-associated secretory phenotype.

Authors:  Corinne Albiges-Rizo; Hans Van Oosterwyck; Eva Faurobert; Daphné Raphaëlle Vannier; Apeksha Shapeti; Florent Chuffart; Emmanuelle Planus; Sandra Manet; Paul Rivier; Olivier Destaing
Journal:  Angiogenesis       Date:  2021-08-03       Impact factor: 9.596

7.  PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.

Authors:  Aileen A Ren; Daniel A Snellings; Yourong S Su; Courtney C Hong; Marco Castro; Alan T Tang; Matthew R Detter; Nicholas Hobson; Romuald Girard; Sharbel Romanos; Rhonda Lightle; Thomas Moore; Robert Shenkar; Christian Benavides; M Makenzie Beaman; Helge Müller-Fielitz; Mei Chen; Patricia Mericko; Jisheng Yang; Derek C Sung; Michael T Lawton; J Michael Ruppert; Markus Schwaninger; Jakob Körbelin; Michael Potente; Issam A Awad; Douglas A Marchuk; Mark L Kahn
Journal:  Nature       Date:  2021-04-28       Impact factor: 49.962

8.  Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage.

Authors:  Je Yeong Sone; Yan Li; Nicholas Hobson; Sharbel G Romanos; Abhinav Srinath; Seán B Lyne; Abdallah Shkoukani; Julián Carrión-Penagos; Agnieszka Stadnik; Kristina Piedad; Rhonda Lightle; Thomas Moore; Ying Li; Dehua Bi; Robert Shenkar; Timothy Carroll; Yuan Ji; Romuald Girard; Issam A Awad
Journal:  J Cereb Blood Flow Metab       Date:  2021-05-26       Impact factor: 6.960

9.  Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance.

Authors:  Julián Carrión-Penagos; Hussein A Zeineddine; Sean P Polster; Romuald Girard; Seán B Lyne; Janne Koskimäki; Sharbel Romanos; Abhinav Srinath; Dongdong Zhang; Ying Cao; Agnieszka Stadnik; Kristina Piedad; Robert Shenkar; Issam A Awad
Journal:  J Neurosurg       Date:  2020-04-03       Impact factor: 5.115

10.  Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.

Authors:  Miguel Alejandro Lopez-Ramirez; Catherine Chinhchu Lai; Shady Ibrahim Soliman; Preston Hale; Angela Pham; Esau J Estrada; Sara McCurdy; Romuald Girard; Riya Verma; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Robert Shenkar; Orit Poulsen; Gabriel G Haddad; Richard Daneman; Brendan Gongol; Hao Sun; Frederic Lagarrigue; Issam A Awad; Mark H Ginsberg
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.